- Home
- SLNO vs ZLAB Comparison
SLNO vs ZLAB Comparison
Compare SLNO & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLNO
- ZLAB
- Stock Information
- Founded
- SLNO 1999
- ZLAB 2013
- Country
- SLNO United States
- ZLAB China
- Employees
- SLNO N/A
- ZLAB N/A
- Industry
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- SLNO Health Care
- ZLAB Health Care
- Exchange
- SLNO Nasdaq
- ZLAB Nasdaq
- Market Cap
- SLNO 3.8B
- ZLAB 3.6B
- IPO Year
- SLNO 2014
- ZLAB 2017
- Fundamental
- Price
- SLNO $82.27
- ZLAB $32.54
- Analyst Decision
- SLNO Strong Buy
- ZLAB Buy
- Analyst Count
- SLNO 9
- ZLAB 5
- Target Price
- SLNO $105.11
- ZLAB $54.28
- AVG Volume (30 Days)
- SLNO 1.4M
- ZLAB 781.8K
- Earning Date
- SLNO 08-06-2025
- ZLAB 08-05-2025
- Dividend Yield
- SLNO N/A
- ZLAB N/A
- EPS Growth
- SLNO N/A
- ZLAB N/A
- EPS
- SLNO N/A
- ZLAB N/A
- Revenue
- SLNO N/A
- ZLAB $418,326,000.00
- Revenue This Year
- SLNO N/A
- ZLAB $44.07
- Revenue Next Year
- SLNO N/A
- ZLAB $49.13
- P/E Ratio
- SLNO N/A
- ZLAB N/A
- Revenue Growth
- SLNO N/A
- ZLAB 43.72
- 52 Week Low
- SLNO $41.50
- ZLAB $16.01
- 52 Week High
- SLNO $90.32
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- SLNO 51.33
- ZLAB 40.19
- Support Level
- SLNO $79.70
- ZLAB $34.26
- Resistance Level
- SLNO $90.32
- ZLAB $35.72
- Average True Range (ATR)
- SLNO 3.66
- ZLAB 1.12
- MACD
- SLNO -0.41
- ZLAB -0.54
- Stochastic Oscillator
- SLNO 31.42
- ZLAB 3.83
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.